Cyted Health Secures €37.5M Series B to Advance Esophageal Cancer Diagnostics Platform
Key Insights
Cambridge-based Cyted Health (search) raised €37.5 million in Series B funding led by EQT Life Sciences (search), Advent Life Sciences (search), and British Business Bank (search) to accelerate US commercial expansion of its esophageal cancer (search) diagnostics platform.
The company has developed the FDA 510(k)-cleared EndoSign (search) device for minimally invasive esophageal cell collection, which combined with molecular testing detects pre-cancerous, cancerous, and inflammatory esophageal conditions.
Cyted's diagnostic platform has already completed over 35,000 tests across the NHS and is conducting the DETECT-ME clinical validation study enrolling US patients since March 2025.
Cambridge-based Cyted Health (search) has secured €37.5 million in Series B financing to accelerate the commercial expansion of its esophageal cancer (search) diagnostics platform in the United States. The round was led by EQT Life Sciences (search), Advent Life Sciences (search), and the British Business Bank (search), with continued support from existing investors Morningside (search) and BGF (search).
The funding represents a significant milestone for the gastrointestinal molecular diagnostics company, which focuses on improving early detection and prevention of oesophageal adenocarcinoma (search) through minimally invasive cell collection coupled with proprietary biomarker discovery.
Proven Clinical Platform Shows Strong Market Traction
Cyted Health (search)'s diagnostic platform has demonstrated substantial clinical success, completing over 35,000 tests across the NHS and building a robust portfolio of peer-reviewed publications. The company's technology centers on the FDA 510(k)-cleared EndoSign (search) device, which enables minimally invasive esophageal cell collection combined with advanced molecular testing to detect pre-cancerous, cancerous, and inflammatory esophageal conditions.
Founded in 2020 by experts at the University of Cambridge, the company has established itself as a pioneer in the early detection space for one of the world's deadliest cancers. Oesophageal cancer (search) maintains a survival rate of only 20% globally, highlighting the critical need for improved early intervention strategies.
Strategic US Expansion and Portfolio Development
The Series B financing will primarily support the commercial expansion of Cyted's diagnostics platform in the US market while consolidating the company's existing commercial success across the UK. Additionally, the funding will enable expansion of the company's portfolio of advanced medical diagnostics tests.
"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier," said Marcel Gehrung, CEO and co-founder of Cyted Health (search). "This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."
Clinical Validation and Market Position
The company is currently conducting the DETECT-ME clinical validation study, which has been enrolling US patients since March 2025 to further validate its newest assays. This ongoing clinical work supports Cyted's position in the broader cancer diagnostics space, where it operates alongside companies like Exact Sciences (search) and Guardant Health.
Carmine Circelli, director of life sciences at British Business Bank (search), emphasized the investment's significance: "Cyted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally."
The British Business Bank (search) contributed £5 million to the funding round, demonstrating strong institutional support for the company's mission to address critical unmet needs in esophageal cancer (search) detection and prevention.